A dry powder inhaler formulation provides excellent protection against pneumonia-causing bacteria, scientists report. Community-acquired pneumonia, a type of lung inflammation contracted outside ...

A case study will also be presented, in which an inhaled formulation of the antibody bevacizumab demonstrated 24-month stability at 25°C. Key Learning Objectives. Understand formulation approaches for ...

Successful drug delivery via a dry powder inhaler is determined by the API physicochemical properties, the formulation composition and process, the device and operating conditions, the patient–device ...

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the ...

LONDON, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical compa ...

LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 ...

ProAir RespiClick will be available as a dry-powder inhaler containing 200 actuations and 0.65g of the formulation. Each dose delivers 108mcg of albuterol sulfate (equivalent to 90mcg of albuterol ...

DALLAS — A dry powder formulation of treprostinil was safe and well tolerated at 2 months, with no drug-related serious adverse events, in patients with pulmonary arterial hypertension ...

CRYSTAL LAKE, Ill., November 07, 2024--Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform ...